Healthcare Aug 02, 2021 09:42 AM (GMT+8)
Billion Europe health news on August 2, Bodong medicine recently announced that it had completed a c-round financing of more than US $100 million. This round of financing was jointly led by the old shareholder Hillhouse venture capital and the strategic investor Philips. Goldman Sachs asset management and Boyu capital participated in the joint lead investment. Lead capital and the old shareholder BoChang capital followed the investment. Haoyue capital served as the exclusive financial adviser for this round of financing. The current round of financing funds will be used to accelerate the commercialization of the company's products, new product research and development, clinical registration, and further improve the global layout of vascular interventional diagnosis and treatment.
Founded in Shanghai in September 2015, Bodong medicine is co founded by the industry senior management team and the world's top scientists. It is committed to becoming the industry leader of global vascular interventional diagnosis and treatment. The company's products cover a complete industrial chain of vascular interventional diagnosis and treatment, such as accurate screening of vascular diseases, intraoperative diagnosis and surgical planning, postoperative efficacy evaluation and patient risk prediction. Up to now, Bodong medicine has more than 70 patents from China, the United States, Germany and Japan, and many of the world's first top technologies.
Bodong medicine has the world's richest vascular interventional diagnosis and treatment product line, and its business model covers a variety of ways such as equipment, consumables and services. Its pioneering coronary artery noninvasive FFR diagnosis and PCI surgical navigation technology (QFR) based on intraoperative DSA imaging are the world's first, and has the world's leading ct-ffr system (ct-qfr), the world's first intraoperative multimodal endovascular imaging physiology equipment, eagle eye series interventional consumables product line (including the world's first IVUS / OCT / QFR three in one catheter, Oct IVUS dual-mode and single-mode catheters and other products).
This text is a result of machine translation.